Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
13th Nov 2006, 10:10 GMT
VENLO, THE NETHERLANDS (MARKET WIRE) QIAGEN, (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) the world's leading provider of products for pre-analytical sample preparation and a leader in molecular diagnostics, has introduced FlexiPlate siRNA, the worldwide first product line for fully customized sets of siRNAs for RNA Interference (RNAi) research.
Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products related news:
- QIAGEN Introduces Novel Technology for Customized RNAi Assay Products — PR Newswire: All Releases
- Google introduces customized home pages for groups (Reuters) — Yahoo! News: Technology News
- Keithley Introduces PXI Products for Hybrid Test Systems in Production Applications — StratWire - Business of Healthcare NewsFeed
- Tabelle: Qiagen NV - 3. Quartal 2006 — Finanztreff.de / BRANCHEN
- SCOLR Pharma Partner Introduces 3 New Products Based on SCOLR Technology — Operations-Related News from StratCenter.com
- New Archive Attender® V 3.0 Takes Aim at Efficiency by Offering a Rapid, 15-Minute Installation — PR Leap - Technology News Releases
- QIAGEN-Zahlen treffen Erwartungen — Nachrichten Ticker - www.finanzen.net
- Qiagen erfüllt im 3Q eigene Prognose - Einmaleffekte belasten — Finanztreff.de / BRANCHEN
- Google introduces customized home pages for groups — Reuters: Internet
- Google Apps to offer customized home pages — Technology news - CNNMoney.com
Latest news from Market Wire - Pharmaceuticals and Biotech:
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech
- GelStat Corporation: GelStat Announces the Retention of Accomplished Business Development and Marketing Firm U.S. Marketing